专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005089797A2 SUPPORT SYSTEM IN THE FORM OF PROTEIN-BASED NANOPARTICLES FOR THE CELL-SPECIFIC ENRICHMENT OF PHARMACEUTICALLY ACTIVE SUBSTANCES 审中-公开
标题翻译：在纳米颗粒中ON蛋白的形式支持系统基于对药物活性物质HOST细胞 - 特异性富集
公开(公告)号：WO2005089797A2
公开(公告)日：2005-09-29
申请号：PCT/EP2005002185
申请日：2005-03-02
申请人： LOHMANN THERAPIE SYST LTS , BALTHASAR SABINE , VON BRIESEN HAGEN , DINAUER NORBERT , KREUTER JOERG , LANGER KLAUS , WARTLICK HEIDRUN
发明人： BALTHASAR SABINE , VON BRIESEN HAGEN , DINAUER NORBERT , KREUTER JOERG , LANGER KLAUS , WARTLICK HEIDRUN
IPC分类号： A61K9/51 , A61K39/395 , A61K47/42 , A61K47/48
CPC分类号： A61K9/5169 , A61K9/5192 , A61K47/551 , A61K47/62 , A61K47/6849 , A61K47/6855 , A61K47/6931 , B82Y5/00
摘要： The invention relates to a support system in the form of protein-based nanoparticles for the cell-specific, intracellular enrichment of at least one pharmacologically active substance, which has structures that are coupled by means of reactive groups. Said structures enable a cell-specific attachment and cellular absorption of the nanoparticles. The invention also relates to a method for producing said system.
摘要翻译：以纳米颗粒的形式的载体系统基于隔离的具有耦合结构，这使纳米颗粒及其生产细胞特异性附着和细胞摄取以及方法反应性基团的至少一种药理学活性剂的特定的细胞内积累的蛋白。

2. 发明申请

WO2007104422A8 AGENT-ENRICHED NANOPARTICLES BASED ON HYDROPHILIC PROTEINS 审中-公开
标题翻译：基于亲水性蛋白质ACTIVE纳米粒
公开(公告)号：WO2007104422A8
公开(公告)日：2007-11-08
申请号：PCT/EP2007001675
申请日：2007-02-27
申请人： LOHMANN THERAPIE SYST LTS , KREUTER JOERG , LANGER KLAUS , MICHAELIS KERSTIN , HEKMATARA TELLI , DREIS SEBASTIAN
发明人： KREUTER JOERG , LANGER KLAUS , MICHAELIS KERSTIN , HEKMATARA TELLI , DREIS SEBASTIAN
CPC分类号： A61K31/451 , A61K47/62 , A61K47/643 , A61K47/6931 , B82Y5/00
摘要： The invention relates to agent-enriched nanoparticles that are based on a hydrophilic protein or a combination of hydrophilic proteins in which functional proteins or peptide fragments are bound to the nanoparticles via polyethylene glycol-a-maleic acid imide-?-NHS esters. Also disclosed are methods for producing said nanoparticles and the use thereof.
摘要翻译：本发明涉及一种基于亲水性蛋白或其中通过聚乙二醇 - 一 - 马来酰亚胺功能蛋白质或肽片段的亲水性蛋白的组合活性化合物fbeladene纳米颗粒 - ？ - NHS-酯附着到纳米颗粒，它们的制备和它们的用途。

3. 发明申请

WO2007073932A2 PROTEIN-BASED DELIVERY SYSTEM FOR OVERCOMING RESISTANCE IN TUMOUR CELLS 审中-公开
标题翻译：基于蛋白质输送系统克服抗肿瘤细胞
公开(公告)号：WO2007073932A2
公开(公告)日：2007-07-05
申请号：PCT/EP2006012524
申请日：2006-12-22
申请人： LOHMANN THERAPIE SYST LTS , DREIS SEBASTIAN , LANGER KLAUS , KREUTER JOERG , MICHAELIS MARTIN , CINATL JINDRICH
发明人： DREIS SEBASTIAN , LANGER KLAUS , KREUTER JOERG , MICHAELIS MARTIN , CINATL JINDRICH
CPC分类号： A61K9/1658 , A61K9/0019 , A61K9/5169 , A61K9/5192
摘要： The invention relates to nanoparticles, the particle matrix of which is based on at least one protein in which at least one active agent is embedded, a method of production of the nanoparticles with at least one active agent embedded in t the protein matrix and the use of said nanoparticles for the treatment of tumours, in particular, for the treatment of tumours which are resistant to chemical medicaments.
摘要翻译：本发明涉及纳米颗粒，其颗粒基质基于至少一种蛋白质并且被嵌入在所述至少一种活性成分，用于制备纳米颗粒与至少一个参与活性化合物的蛋白质基质，并使用这样的纳米颗粒对于肿瘤的治疗，特别是用于治疗肿瘤的方法，其是对化疗有抗性。

4. 发明申请

WO2007104422A3 AGENT-ENRICHED NANOPARTICLES BASED ON HYDROPHILIC PROTEINS 审中-公开
标题翻译：基于亲水性蛋白质ACTIVE纳米粒
公开(公告)号：WO2007104422A3
公开(公告)日：2008-03-20
申请号：PCT/EP2007001675
申请日：2007-02-27
申请人： LOHMANN THERAPIE SYST LTS , KREUTER JOERG , LANGER KLAUS , MICHAELIS KERSTIN , HEKMATARA TELLI , DREIS SEBASTIAN
发明人： KREUTER JOERG , LANGER KLAUS , MICHAELIS KERSTIN , HEKMATARA TELLI , DREIS SEBASTIAN
IPC分类号： A61K47/48 , A61K31/451
CPC分类号： A61K31/451 , A61K47/62 , A61K47/643 , A61K47/6931 , B82Y5/00
摘要： The invention relates to agent-enriched nanoparticles that are based on a hydrophilic protein or a combination of hydrophilic proteins in which functional proteins or peptide fragments are bound to the nanoparticles via polyethylene glycol-a-maleic acid imide-?-NHS esters. Also disclosed are methods for producing said nanoparticles and the use thereof.
摘要翻译：本发明涉及一种基于亲水性蛋白或其中通过聚乙二醇 - 一 - 马来酰亚胺功能蛋白质或肽片段的亲水性蛋白的组合活性化合物fbeladene纳米颗粒 - ？ - NHS-酯附着到纳米颗粒，它们的制备和它们的用途。

5. 发明申请

WO2007110152A3 POLYLACTIDE NANOPARTICLES 审中-公开
标题翻译：聚乳酸纳米粒子
公开(公告)号：WO2007110152A3
公开(公告)日：2008-02-21
申请号：PCT/EP2007002198
申请日：2007-03-13
申请人： LOHMANN THERAPIE SYST LTS , KREUTER JOERG , GELPERINA SVETLANA , MAKSIMENKO OLGA , KHALANSKIY ALEXANDER
发明人： KREUTER JOERG , GELPERINA SVETLANA , MAKSIMENKO OLGA , KHALANSKIY ALEXANDER
IPC分类号： A61K9/51 , A61K31/704
CPC分类号： A61K9/5153 , A61K9/0085 , A61K9/19 , A61K9/5192 , A61K31/704
摘要： The present invention relates to a system for targeted active substance delivery for administering a pharmacologically active substance to the central nervous system of a mammal across the blood-brain barrier, where the system for targeted drug delivery comprises nanoparticles of PoIy(DL-lactide) and/or PoIy (DL-lactide-co-glycolide, and at least one pharmacologically active substance which is absorbed in the nanoparticles, is adsorbed thereon or is incorporated therein, and either comprises TPGS or includes a coating of the surface-active substance Pluronic 188, which is deposited on the nanoparticles loaded with active substance, and to methods for producing the system for targeted active substance delivery and to the use of the system for targeted active substance delivery for the treatment of a disease or an impairment of the central nervous system.
摘要翻译：本发明涉及一种用于药物通过血 - 脑屏障，该系统用于靶向药物递送，聚的纳米颗粒（DL-丙交酯）和/或聚药理活性物质给予哺乳动物的中枢神经系统中定位（一个系统DL 丙交酯 - 共 - 乙交酯和其在纳米颗粒吸收的药理学活性物质，被吸收到或结合在所述至少包含，并且或者TPGS包含或表面活性剂的Pluronic 188装载在与活性成分的涂层沉积的纳米颗粒，其包含，和用于制造该药物靶向系统的供应和用于靶向药物递送用于治疗疾病的或中枢神经系统病症使用该系统的方法。

6. 发明申请

WO2007110152A8 POLYLACTIDE NANOPARTICLES 审中-公开
标题翻译：聚乳酸纳米粒子
公开(公告)号：WO2007110152A8
公开(公告)日：2007-12-13
申请号：PCT/EP2007002198
申请日：2007-03-13
申请人： LOHMANN THERAPIE SYST LTS , KREUTER JOERG , GELPERINA SVETLANA , MAKSIMENKO OLGA , KHALANSKIY ALEXANDER
发明人： KREUTER JOERG , GELPERINA SVETLANA , MAKSIMENKO OLGA , KHALANSKIY ALEXANDER
IPC分类号： A61K9/51 , A61K31/704
CPC分类号： A61K9/5153 , A61K9/0085 , A61K9/19 , A61K9/5192 , A61K31/704
摘要： The present invention relates to a system for targeted active substance delivery for administering a pharmacologically active substance to the central nervous system of a mammal across the blood-brain barrier, where the system for targeted drug delivery comprises nanoparticles of PoIy(DL-lactide) and/or PoIy (DL-lactide-co-glycolide, and at least one pharmacologically active substance which is absorbed in the nanoparticles, is adsorbed thereon or is incorporated therein, and either comprises TPGS or includes a coating of the surface-active substance Pluronic 188, which is deposited on the nanoparticles loaded with active substance, and to methods for producing the system for targeted active substance delivery and to the use of the system for targeted active substance delivery for the treatment of a disease or an impairment of the central nervous system.
摘要翻译：本发明涉及一种用于药物通过血 - 脑屏障，该系统用于靶向药物递送，聚的纳米颗粒（DL-丙交酯）和/或聚药理活性物质给予哺乳动物的中枢神经系统中定位（一个系统DL 丙交酯 - 共 - 乙交酯和其在纳米颗粒吸收的药理学活性物质，被吸收到或结合在所述至少包含，并且或者TPGS包含或表面活性剂的Pluronic 188装载在与活性成分的涂层沉积的纳米颗粒，其包含，和用于制造该药物靶向系统的供应和用于靶向药物递送用于治疗疾病的或中枢神经系统病症使用该系统的方法。

7. 发明专利

DE102005062440B4 Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen 未知
公开(公告)号：DE102005062440B4
公开(公告)日：2011-02-24
申请号：DE102005062440
申请日：2005-12-27
申请人： LOHMANN THERAPIE SYST LTS
发明人： DREIS SEBASTIAN , LANGER KLAUS , KREUTER JOERG , MICHAELIS MARTIN , CINATL JINDRICH
IPC分类号： A61K38/02 , A61K9/00 , A61K47/42 , A61P35/00

8. 发明专利

IN8036DE2008A Polylactide nanoparticles 未知
公开(公告)号：IN8036DE2008A
公开(公告)日：2009-03-20
申请号：IN8036DE2008
申请日：2008-09-24
申请人： LOHMANN THERAPIE SYST LTS
发明人： GELPERINA SVETLANA , MAKSIMENKO OLGA , KREUTER JOERG , KHALANSKIY ALEXANDER
摘要： Drug delivery system for the targeted supply of a pharmaceutical substance to the central nervous system of a mammal over the blood-brain barrier, comprises: nanoparticles of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide)(PLGA); and at least a pharmaceutical substance, which is absorbed or incorporated in or adsorbed at the nanoparticles, where the drug deliver system contains d-alpha tocopheryl polyethylene glycol succinate (TPGS) or exhibits a coat on a surface-active material, which is deposited on the nanoparticles that are loaded with the active substance. Drug delivery system for the targeted supply of a pharmaceutical substance to the central nervous system of a mammal over the blood-brain barrier, comprises: nanoparticles of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide) (PLGA); and at least a pharmaceutical substance, which is absorbed or incorporated in or adsorbed at the nanoparticles, where the drug deliver system contains d-alpha tocopheryl polyethylene glycol succinate (TPGS) or exhibits a coat on the surface-active material Pluronic 188 (RTM: Non-ionic block copolymers based on ethylene oxide and propylene oxide) or Poloxamer 188 (RTM: Non-ionic block copolymers based on ethylene oxide and propylene oxide) (A), which is deposited on the nanoparticles that are loaded with the active substance. Independent claims are included for: (1) a procedure for the production of drug delivery system for the targeted supply of a pharmaceutical substance to the central nervous system of a mammal over the blood-brain barrier, comprising dissolving poly(DL-lactide) and/or poly(DL-lactide-co-glycolide) as well as at least a pharmaceutical substance and alternatively a lipid compound in an organic solvent, in order to obtain an organic phase; pouring the organic phase into an aqueous solution containing TPGS; emulsifying the mixture, in order to receive a primary emulsion; homogenizing the primary emulsion; removing the organic solvent from the primary emulsion; and filtering the resulting nano-suspension, which contains nanoparticles loaded with the active substance; and (2) a procedure for the treatment of an disease or a disorder of the central nervous system of a mammal, comprising preparing nanoparticles loaded with the active substance made of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide); covering of the PLGA nano particle loaded with the active substance with (A); administrating the nanoparticles, which are loaded with the active substance and covered with (A), to the blood circulatory system of a mammal; and releasing the active substance, so that it can unfold its pharmacological effect. ACTIVITY : CNS-Gen; Cytostatic. MECHANISM OF ACTION : None given.

9. 发明专利

DE102007006663A1 未知
公开(公告)号：DE102007006663A1
公开(公告)日：2008-08-21
申请号：DE102007006663
申请日：2007-02-10
申请人： LOHMANN THERAPIE SYST LTS
发明人： KREUTER JOERG , LANGER KLAUS , DREIS SEBASTIAN , HEKMATARA TELLI
IPC分类号： A61K38/02

10. 发明专利

CA2646447A1 AGENT-ENRICHED NANOPARTICLES BASED ON HYDROPHILIC PROTEINS 未知
公开(公告)号：CA2646447A1
公开(公告)日：2007-09-20
申请号：CA2646447
申请日：2007-02-27
申请人： LOHMANN THERAPIE SYST LTS
发明人： KREUTER JOERG , LANGER KLAUS , DREIS SEBASTIAN , MICHAELIS KERSTIN , HEKMATARA TELLI
IPC分类号： A61K47/48 , A61K31/451
摘要： Active agent-loaded nanoparticles that are based on a hydrophilic protein or a combination of hydrophilic proteins, and methods for producing the nanoparticles and the use thereof. Functional proteins or peptide fragments are bound to the nanoparticles via polyethylene glycol-alpha-maleimide-omega-NHS esters.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式